Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Ashley Evan Ross, M.D., Ph.D.
Associate Professor of Oncology
Expertise: Benign Prostatic Hyperplasia (BPH), Bladder Cancer, Prostate Cancer, Urology
Research Interests: Developing Novel Therapeutics and Diagnostics in Prostate Cancer
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
The Johns Hopkins Hospital
Appointment Phone: 410-955-6100
600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map
Johns Hopkins Outpatient Center
601 N. Caroline St.
Baltimore, MD 21287 map
Dr. Ashley Evan Ross is an associate professor of urology, oncology and pathology at the Johns Hopkins School of Medicine. His clinical practice focuses on prostate cancer and prostatic diseases.
He has expertise in open and robotic treatment of prostate cancer as well as in focal and salvage prostate cryotherapy and in the active surveillance of prostate cancer. Additionally, Dr. Ross has experience in the treatment of benign prostatic hyperplasia through the use of transurethral resection, laser photo-vaporization and open surgical approaches. As an active member of the Sidney Kimmel Comprehensive Cancer Center, Dr. Ross offers multidisciplinary approaches to the treatment of prostate cancer.
Dr. Ross received his undergraduate degree in biochemistry from the University of Maryland. He earned his graduate and medical degrees from the Johns Hopkins School of Medicine. Dr. Ross joined the faculty in 2012 after completing his general surgery and urology residency and fellowship at Johns Hopkins.
Dr. Ross’s research focuses on prostate carcinogenesis. His laboratory investigates molecular mechanisms that drive prostate cancer and is developing and testing novel targeted therapies for this aggressive disease. Dr. Ross is known for his discovery of how to use Relaxin 1 (RLXN1) as a tissue/urine/blood-based biomarker of high-grade prostate cancer.
Dr. Ross has been recognized with numerous awards and honors. He served as the chief resident in the Department of Urology’s residency program at Johns Hopkins. Most recently, he was recognized with a first prize for a paper presentation at the Baltimore-Washington-West Virginia Urology Resident Day. He is a member of the American Urologic Association.
- Associate Professor of Oncology
- MD PhD, Johns Hopkins University School of Medicine (2006)
- Johns Hopkins University School of Medicine / Urology (2012)
- American Board of Urology / Urology (2014)
Research & Publications
Dr. Ross is a fully trained scientist and an expert on prostate carcinogenesis. His research examines the molecular mechanisms that drive prostate cancer, and he develops and tests targeted therapies for treating prostate cancer. Dr. Ross patented his discovery of how to use Relaxin 1 (RLXN1) as a tissue/urine/blood-based biomarker of high-grade prostate cancer.
Dr. Ross’ research focuses on diagnosing high-risk prostate cancer patients. Recent studies used a newly developed clinical test based on the specific pattern of gene expression from the primary tumor to help predict which men with an elevated PSA after radical prostatectomy will go on to develop metastatic disease.
He and his colleagues also analyzed data regarding high-risk prostate cancer patients and identified a new subgroup of men with localized prostate cancer: men at very high risk of having metastasis and death from prostate cancer after prostatectomy.
By better identifying patients who are high risk for metastatic cancer, doctors can offer more effective, targeted prostate cancer treatment.
Dr. Ross’ laboratory investigates the molecular mechanisms that drive prostate cancer. He is developing and testing novel targeted therapies for this aggressive disease. Additionally, researchers in his lab are developing tests to guide the best diagnostic and treatment selection for each individual prostate cancer patient.
Selected PublicationsView all on Pubmed
Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE. "Very-high-risk localized prostate cancer: definition and outcomes." Prostate Cancer and Prostatic Disease. 2013 Nov 5. doi: 10.1038/pcan.2013.46. [Epub ahead of print].
Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ. "Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience." Prostate. 2013 Nov;73(15):1673-80. doi: 10.1002/pros.22702. Epub 2013 Sep 9.
Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM. "A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy." Prostate Cancer and Prostatic Disease. 2013 Oct 22. doi: 10.1038/pcan.2013.49. [Epub ahead of print].
Ciolino JB, Stefanescu CF, Ross AE, Salvador-Culla B, Cortez P, Ford EM, Wymbs KA, Sprague SL, Mascoop DR, Rudina SS, Trauger SA, Cade F, Kohane DS. "In vivo performance of a drug-eluting contact lens to treat glaucoma for a month." Biomaterials. 2014 Jan;35(1):432-9. doi: 10.1016/j.biomaterials.2013.09.032. Epub 2013 Oct 4.
Fang H, Pajski ML, Ross AE, Venton BJ. "Quantitation of dopamine, serotonin and adenosine content in a tissue punch from a brain slice using capillary electrophoresis with fast-scan cyclic voltammetry detection." Analytical methods: advancing methods and applications. 2013;5(11):2704-2711.
Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humpreys EB, Faraj S, Bezerra, Han M, Partin AW, Trock BJ, Schaeffer EM. Tissue Based Genomics Augment Post-Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology. Eur Urol 2015 Jun 6 [Epub ahead of print] PubMed PMID: 26058959.
Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, Davicioni E, Feng FY. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2015 May 19. doi: 10.1038/pcan.2015.22. [Epub ahead of print] PubMed PMID: 25986914.]
Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY. Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. Eur Urol. 2015 May 8. pii: S0302-2838(15)00375-9. doi: 10.1016/j.eururo.2015.04.033. [Epub ahead of print] PubMed PMID: 25964175.
Carvalho FL, Marchionni L, Gupta A, Kummangal BA, Schaeffer EM, Ross AE, Berman DM. HES6 promotes prostate cancer aggressiveness independently of Notch signalling. J Cell Mol Med. 2015 Apr 12. doi: 10.1111/jcmm.12537. [Epub ahead of print] PubMed PMID: 25864518.
Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate and High Risk Men. Eur Urol. 2015 Apr 25. pii: S0302-2838(15)00318-8. doi: 10.1016/j.eururo.2015.04.016. [Epub ahead of print] PubMed PMID: 25922274.
Genomic classifiers for non-invasive identification of high grade prostate cancer with metastatic potential
Patent # WO 2014081923 A1 | 05/30/2014
The present invention relates to the field of biomarkers. More specifically, the present invention provides methods and compositions useful for diagnosing and/or prognosing prostate cancer. In a specific embodiment, a method for diagnosing prostate cancer or a likelihood thereof in a patient comprising the steps of (a) obtaining a biological sample from the patient; (b) subjecting the sample to an assay for detecting expression of one or more of ACSM2A, BDH2, C19orf51, C8orf76, CGB5, CSMD3, DAZ2, DUX4, FAM22G, FAM90A1, GABBR2, GRM3, HMMR, HOXC4, KAAG1, KRIT1, KRTAP20-1, LOC392196, LOC441956, LOC650293, LTB4R, METTL7B, NEK2, OR11H12, OR2J3, OR2L8, OR2M1P, OR2T3, OR4F5, OR52A4, OR52I1, PGA3, PHACTR3, PMP2, PRAMEF6, PSG1, SIGLEC10, SOX11, SPDYE1, SSX1, TCEB3B, TCFL5, TFAP2D, TSPY2, UGT2B10, UGT2B11, UGT2B28, WDR49, and WFDC5; and (c) determining that the patient has prostate cancer or a likelihood thereof if the expression of the one or more biomarkers is increased relative to a reference non-prostate cancer sample.
Activities & Honors
- DOD Prostate cancer PTRA Award, 2013
- AUA Annual Meeting Best of Posters Award, MP83: Prostate Cancer: Markers (II), 2013
- Johns Hopkins Clinical Scientist Award, Johns Hopkins, 2013
- Honorable Mention, Johns Hopkins University Eight Annual Prostate Research Day, 2013
- First Prize, Paper Presentation, Baltimore-Washington-West Virginia Urology Resident Day, 2012
- Honorable Mention, Johns Hopkins University Seventh Annual Prostate Research Day, 2012
- Chief Resident, Johns Hopkins Medical Institution, 2010 - 2012
- Honorable Mention, Johns Hopkins University Fifth Annual Prostate Research Day, 2010
- Osler Medical Housestaff Teaching Award, Johns Hopkins Department of Medicine , 2009
- Catch A Shining Star Annual Award Winner, Johns Hopkins Hospital, 2008
- Shining Star Award, Johns Hopkins Bayview Medical Center , 2008
- Surgery Clerkship Teaching Award, Johns Hopkins Hospital, 2007
- Shining Star Award, Johns Hopkins Bayview Medical Center , 2007
- Surgical Intern of the Year, Johns Hopkins Hospital, 2006
- Academy of Achievement Award, 2006
- Pathology Young Investigator’s Award for Excellence in Clinical Research, 2005
- Medical Scientist Training Program Fellowship, 1997
- Undergraduate Research Fellowship, Howard Hughes Medical Institute , 1996
- University of Maryland Senior Summer Scholarship, University of Maryland , 1996
- Junior Merck Index Award, 1996
- Alpha Omega Alpha (AOA), 2006
- American Urologic Association, 2008